MIMOSA Pro near-infrared tissue oxygen imaging compared with standard leg vascular tests

Correlating Multispectral Near-Infrared Imaging to Standard Vascular Diagnostics

Observational MIMOSA Diagnostics Inc. · NCT06899113

This project tries to see if the MIMOSA Pro near‑infrared camera can measure leg tissue oxygen as well as standard vascular tests in adults having lower‑limb vascular assessments.

Quick facts

Study typeObservational
Enrollment60 (estimated)
Ages18 Years and up
SexAll
SponsorMIMOSA Diagnostics Inc. Industry-sponsored
Drugs / interventionsradiation
Locations1 site (Lake Success, New York)
Trial IDNCT06899113 on ClinicalTrials.gov

What this trial studies

This observational, non‑interventional study at a Northwell Health wound center will image adults undergoing ankle‑brachial index (ABI) and related vascular tests using the MIMOSA Pro multispectral near‑infrared device. Investigators will record tissue oxygen saturation (StO2) from MS‑NIR imaging and compare those measures to ABI, toe‑brachial index (TBI), transcutaneous oxygen (TcPO2), and Doppler waveforms, as well as to PAD/venous disease and wound stage classifications. No clinical decisions will be made based on MIMOSA results and participants will follow standard care; imaging is performed as an adjunct and participants will be followed for about two months during routine visits. The analysis will focus on correlation between modalities and how often MS‑NIR provides usable vascular information compared with standard tools.

Who should consider this trial

Good fit: Adults (18+) who are undergoing an ABI and additional vascular testing for peripheral vascular disease or lower‑limb wounds, can give informed consent, and can be followed by the same clinical team for the study period.

Not a fit: Patients receiving radiation to the limb, those with active Charcot joints, individuals unable to provide informed consent, or people already enrolled in another ulcer management trial may not benefit from or be eligible for this protocol.

Why it matters

Potential benefit: If successful, MIMOSA Pro imaging could provide a fast, non‑contact way to identify tissue oxygen deficits and support vascular and wound assessments in clinic.

How similar studies have performed: Prior small studies of near‑infrared spectroscopy or imaging have shown promising correlations with tissue oxygenation, but larger clinical validation in wound care settings remains limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged 18 and older
* Patient is undergoing an ABI test.
* Patient recently had/will have further vascular assessment, as per standard of care (inc. transcutaneous oxygen pressure, Doppler waveforms)
* Patients who can be followed by the same investigating team for the whole period of their participation in the study.

Exclusion Criteria:

* Patients who are participating in another clinical study for ulcer management
* Patients who are unable to understand the aims of the study and not able to provide informed consent
* Receiving radiation to the extremity
* Active charcot joints

Where this trial is running

Lake Success, New York

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Vascular Disease, PeripheralChronic Wound of the Lower Limbmultispectral near-infrared spectroscopychronic woundperipheral vascular diseasenear-infrared imagingABItissue oxygenation
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.